[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335112-105":59,"doc-detail-335112-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-pi3k-family-with-small-molecule-inhibitors-in-cancer-therapy-current-clinical-status-and-future-directions","Targeting PI3K family with small-molecule inhibitors in cancer therapy - current clinical status and future directions","","The PI3K (phosphatidylinositol-3-kinase) family consists of three classes of intracellular enzymes that regulate growth, division, migration, and survival. Aberrant PI3K pathway activation disrupts cellular metabolism and is associated with cancer onset. Five FDA-approved class I PI3K small-molecule inhibitors are used mainly for breast cancer and hematologic malignancies, yet they differ in selectivity across class I members. This review summarizes PI3K structures and roles in cancer progression, critically evaluates class I PI3K inhibitors and their clinical applications, and proposes future therapeutic directions by identifying intervention-amenable molecular targets.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-pi3k-family-with-small-molecule-inhibitors-in-cancer-therapy-current-clinical-status-and-future-directions/335112/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-pi3k-family-with-small-molecule-inhibitors-in-cancer-therapy-current-clinical-status-and-future-directions/335112.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does the PI3K signaling network play under normal and cancer conditions?","Question",{"text":112,"@type":113},"Under normal physiology, PI3K signaling orchestrates cell growth, division, migration, and survival. Aberrant activation disrupts cellular activity and metabolism, often marking the onset of cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many class I PI3K inhibitors have been approved by the FDA, and for which cancers are they primarily used?",{"text":117,"@type":113},"The FDA has approved five class I PI3K inhibitors. They are primarily used for breast cancer and hematologic malignancies.",{"name":119,"@type":110,"acceptedAnswer":120},"What does the review focus on regarding PI3K inhibitors?",{"text":121,"@type":113},"It summarizes PI3K structures and their functional roles, critically evaluates small-molecule inhibitors targeting class I PI3K, and emphasizes their clinical applications in cancer treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335112,1790328350,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Li etal. Molecular Cancer (2024) 23:164 Molecular Cancer  \n[https://doi.org/10.1186/s12943-024-02072-1](https://doi.org/10.1186/s12943-024-02072-1)  \n REVIEW Open Access  \nTargeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions  \nHongyao Li1,2,3†, Xiang Wen3†, Yueting Ren3,4, Zhichao Fan1,2,3, Jin Zhang5*, Gu He3* and Leilei Fu 1,2*  \nAbstract  \nThe Phosphatidylinositol-3-kinase (PI3K) family is well-known to comprise three classes of intracellular enzymes. Class I PI3Ks primarily function in signaling by responding to cell surface receptor stimulation, while class II and III are more involved in membrane transport. Under normal physiological conditions, the PI3K signaling network orchestrates cell growth, division, migration and survival. Aberrant activation of the PI3K signaling pathway disrupts cellular activity and metabolism, often marking the onset of cancer. Currently, the Food and Drug Administration (FDA) has approved the clinical use of five class I PI3K inhibitors. These small-molecule inhibitors, which exhibit varying selectivity for different class I PI3K family members, are primarily used in the treatment of breast cancer and hematologic malignancies. Therefore, the development of novel class I PI3K inhibitors has been a prominent research focus in the field of oncology, aiming to enhance potential therapeutic selectivity and effectiveness. In this review, we summarize the specific structures of PI3Ks and their functional roles in cancer progression. Additionally, we critically evaluate small molecule inhibitors that target class I PI3K, with a particular focus on their clinical applications in cancer treatment. Moreover, we aim to analyze therapeutic approaches for different types of cancers marked by aberrant PI3K activation and to identify potential molecular targets amenable to intervention with small-molecule inhibitors. Ultimately, we propose future directions for the development of therapeutic strategies that optimize cancer treatment outcomes by modulating the PI3K family.  \nKeywords PI3K family, Class I PI3K, Clinical applications, Therapeutic approach, Molecular target, Small-molecule inhibitor, Cancer therapy  \n†Hongyao Li and Xiang Wen contributed equally to this work.  \n*Correspondence: Jin Zhang [zhangjin1989@szu.edu.cn](zhangjin1989@szu.edu.cn)[ ](zhangjin1989@szu.edu.cn)Gu He  \n[hegu@scu.edu.cn](hegu@scu.edu.cn)[ ](hegu@scu.edu.cn)Leilei Fu [leilei_fu@163.com](leilei_fu@163.com)  \n1 Institute of Precision Drug Innovation and Cancer Center, the Second Hospital of Dalian Medical University, Dalian 116023, China  \n2 Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China  \n3 Department of Dermatology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Sichuan University, Chengdu 610041, China  \n4 Department of Brain Science, Faculty of Medicine, Imperial College, London SW72AZ, UK  \n5 School of Pharmaceutical Sciences of Medical School, Shenzhen University, Shenzhen 518000, China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by ","cbCaifJMj9Bq5Vyi","https://ap.wps.com/l/cbCaifJMj9Bq5Vyi","pdf",7347108,42,"English","# Abstract\n# Introduction","[{\"question\":\"What role does the PI3K signaling network play under normal and cancer conditions?\",\"answer\":\"Under normal physiology, PI3K signaling orchestrates cell growth, division, migration, and survival. Aberrant activation disrupts cellular activity and metabolism, often marking the onset of cancer.\"},{\"question\":\"How many class I PI3K inhibitors have been approved by the FDA, and for which cancers are they primarily used?\",\"answer\":\"The FDA has approved five class I PI3K inhibitors. They are primarily used for breast cancer and hematologic malignancies.\"},{\"question\":\"What does the review focus on regarding PI3K inhibitors?\",\"answer\":\"It summarizes PI3K structures and their functional roles, critically evaluates small-molecule inhibitors targeting class I PI3K, and emphasizes their clinical applications in cancer treatment.\"}]","Targeting PI3K family with small-molecule inhibitors in cancer therapy - current clinical status and future directions | PDF",1790009706,106]